FI962048A - Säädellysti vaikuttavia aineita vapauttavia rakkuloita - Google Patents

Säädellysti vaikuttavia aineita vapauttavia rakkuloita Download PDF

Info

Publication number
FI962048A
FI962048A FI962048A FI962048A FI962048A FI 962048 A FI962048 A FI 962048A FI 962048 A FI962048 A FI 962048A FI 962048 A FI962048 A FI 962048A FI 962048 A FI962048 A FI 962048A
Authority
FI
Finland
Prior art keywords
active substance
biologically active
vesicles
controlled
composition
Prior art date
Application number
FI962048A
Other languages
English (en)
Swedish (sv)
Other versions
FI962048A0 (fi
FI115823B (fi
Inventor
Mantripragada Sankaram
Sinil Kim
Original Assignee
Depotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22548158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI962048(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Depotech Corp filed Critical Depotech Corp
Publication of FI962048A0 publication Critical patent/FI962048A0/fi
Publication of FI962048A publication Critical patent/FI962048A/fi
Application granted granted Critical
Publication of FI115823B publication Critical patent/FI115823B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/08—Systemic pesticides
FI962048A 1993-11-16 1996-05-14 Menetelmä synteettisten membraanivesikkelien valmistamiseksi FI115823B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15365793A 1993-11-16 1993-11-16
US15365793 1993-11-16
PCT/US1994/012957 WO1995013796A1 (en) 1993-11-16 1994-11-10 Vesicles with controlled release of actives
US9412957 1994-11-10

Publications (3)

Publication Number Publication Date
FI962048A0 FI962048A0 (fi) 1996-05-14
FI962048A true FI962048A (fi) 1996-07-15
FI115823B FI115823B (fi) 2005-07-29

Family

ID=22548158

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962048A FI115823B (fi) 1993-11-16 1996-05-14 Menetelmä synteettisten membraanivesikkelien valmistamiseksi

Country Status (25)

Country Link
US (1) US6132766A (fi)
EP (1) EP0729351B1 (fi)
JP (1) JP3002702B2 (fi)
KR (1) KR100241300B1 (fi)
CN (1) CN1099868C (fi)
AT (1) ATE196248T1 (fi)
AU (1) AU686277B2 (fi)
BG (1) BG63146B1 (fi)
BR (1) BR9408072A (fi)
CA (1) CA2176712C (fi)
DE (1) DE69425901T2 (fi)
DK (1) DK0729351T3 (fi)
ES (1) ES2149955T3 (fi)
FI (1) FI115823B (fi)
GR (1) GR3034954T3 (fi)
HU (1) HUT75162A (fi)
IL (1) IL111628A (fi)
NO (1) NO304577B1 (fi)
NZ (1) NZ276305A (fi)
PL (1) PL314485A1 (fi)
PT (1) PT729351E (fi)
RO (1) RO116341B1 (fi)
RU (1) RU2160093C2 (fi)
WO (1) WO1995013796A1 (fi)
ZA (1) ZA949063B (fi)

Families Citing this family (246)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
CN1138533C (zh) 1996-09-13 2004-02-18 利普森有限公司 脂质体
US7384923B2 (en) 1999-05-14 2008-06-10 Lipoxen Technologies Limited Liposomes
CA2269631C (en) * 1996-10-25 2008-03-25 Monsanto Company Composition and method for treating plants with exogenous chemicals
AU755024B2 (en) 1996-10-25 2002-11-28 Monsanto Technology Llc Composition and method for treating plants with exogenous chemicals
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
AU5465498A (en) 1996-12-13 1998-07-03 Michael Kunitani Analysis and separation of platelet-derived growth factor proteins
US5891467A (en) * 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
US6106858A (en) * 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
ATE535232T1 (de) * 1997-09-18 2011-12-15 Pacira Pharmaceuticals Inc Retardierte freisetzung liposomaler anesthetischer zusammensetzungen
EP1900818A3 (en) 1997-11-06 2008-06-11 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigens
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
IL135989A0 (en) 1997-11-14 2001-05-20 Skyepharma Inc Processes for the production of multivesicular liposomes
ES2333071T5 (es) 1998-01-14 2015-08-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos de Neisseria meningitidis
ES2294629T3 (es) 1998-05-01 2008-04-01 Novartis Vaccines And Diagnostics, Inc. Antigenos de neisseria y composiciones.
EP1953229A3 (en) 1998-10-15 2008-12-24 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
EP1141331B1 (en) 1998-12-16 2008-09-17 Novartis Vaccines and Diagnostics, Inc. HUMAN CYCLIN-DEPENDENT KINASE (hPNQALRE)
MXPA01007486A (es) * 1999-01-25 2003-06-24 Optime Therapeutics Inc Formulaciones de liposomas.
PT1228217E (pt) 1999-04-30 2013-01-28 Novartis Vaccines & Diagnostic Antígenos de neisseria conservados
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
WO2001000654A2 (en) 1999-06-29 2001-01-04 Pharmaceutical Discovery Corporation Purification and stabilization of peptide and proteins in pharmaceutical agents
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
ES2539951T3 (es) 1999-10-29 2015-07-07 Novartis Vaccines And Diagnositics S.R.L. Péptidos antigénicos de Neisseria
ES2335386T3 (es) 1999-11-18 2010-03-26 Novartis Vaccines And Diagnostics, Inc. Gen fgf-21 humano y productos de expresion genica.
AU8431301A (en) 1999-12-23 2001-11-20 Neurochem (International) Limited Compounds and methods for modulating cerebral amyloid angiopathy
EP2281571A3 (en) 2000-01-17 2012-04-25 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (omv) vaccine comprising n. meningitidids serogroup b outer membrane proteins
AU3948801A (en) 2000-02-28 2001-09-12 Chiron Spa Heterologous expression of neisserial proteins
US20020082205A1 (en) 2000-03-08 2002-06-27 Nobuyuki Itoh Human FGF-23 gene and gene expression products
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
ES2398391T3 (es) 2000-06-15 2013-03-15 Novartis Vaccines And Diagnostics, Inc. Polinucleótidos relacionados con cáncer de colon
EP2284181A1 (en) 2000-10-27 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A and B
ES2397627T3 (es) 2000-12-07 2013-03-08 Novartis Vaccines And Diagnostics, Inc. Retrovirus endógenos regulados por aumento en el cáncer de próstata
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
KR20030022094A (ko) 2001-05-24 2003-03-15 (주)휴먼디엔에이테크놀로지 모낭에 존재하는 새로운 제 2 케라티노사이트 성장인자유사체
WO2003039491A2 (en) 2001-11-09 2003-05-15 Georgetown University Novel isoforms of vascular endothelial cell growth inhibitor
ES2312649T3 (es) 2001-12-12 2009-03-01 Novartis Vaccines And Diagnostics S.R.L. Inmunizacion frente a chlamydia trachomatis.
SG148035A1 (en) 2002-01-08 2008-12-31 Novartis Vaccines & Diagnostic Gene products differentially expressed in cancerous breast cells and their methods of use
EP1572933A4 (en) 2002-02-13 2007-09-05 Univ Duke MODULATION OF IMMUNE RESPONSE BY POLYPEPTIDES OF RESPONSE TO STRESS BINDING TO NON PEPTIDES
FR2836043B1 (fr) * 2002-02-15 2004-06-04 Inst Nat Sante Rech Med Vesicules lipidiques, preparation et utilisations
EP1894591B1 (en) 2002-03-20 2013-06-26 MannKind Corporation Cartridge for an inhalation apparatus
EP2093233A1 (en) 2002-03-21 2009-08-26 Sagres Discovery, Inc. Novel compositions and methods in cancer
US20040082521A1 (en) * 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
ATE545651T1 (de) 2002-06-13 2012-03-15 Novartis Vaccines & Diagnostic Vektoren zur expression von hml-2-polypeptiden
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
AU2003267984A1 (en) * 2002-07-03 2004-01-23 Receptor Biologix, Inc. Liposomal vaccine
US20040247661A1 (en) * 2002-07-03 2004-12-09 Dov Michaeli Liposomal vaccine
US7135324B2 (en) 2002-09-04 2006-11-14 The University Of Connecticut Viral recombinases, related articles, and methods of use thereof
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
JP2006508126A (ja) * 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド 薬学的製剤のタンパク質安定化されたリポソーム製剤
ATE466875T1 (de) 2002-11-15 2010-05-15 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
CA2921578C (en) 2002-12-24 2017-02-14 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
AU2004213452A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic GPCR targets in cancer
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
EA010159B1 (ru) 2003-02-19 2008-06-30 Ринат Ньюросайенс Корп. Способы лечения боли введением антагониста фактора роста нервов и нестероидного противовоспалительного средства и содержащие их композиции
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2005053605A2 (en) * 2003-09-09 2005-06-16 Gilead Sciences, Inc. Therapeutic liposomes
SG166768A1 (en) 2003-12-23 2010-12-29 Rinat Neuroscience Corp Agonist anti-trkc antibodies and methods using same
NZ548980A (en) * 2004-01-12 2009-10-30 Mannkind Corp Reducing serum proinsulin levels in type 2 diabetics
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
EP1736541B1 (en) 2004-03-29 2013-01-23 Galpharma Co., Ltd. Novel modified galectin 9 protein and use thereof
US7223562B2 (en) 2004-03-31 2007-05-29 New York University Compositions for controlling hair growth
SI1732949T1 (sl) 2004-04-07 2010-05-31 Rinat Neuroscience Corp Postopki za zdravljenje bolečine kostnega raka zdajanjem antagonista živčnega rastnega faktorja
US20050255154A1 (en) * 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
EP1768650B1 (en) * 2004-06-04 2008-07-16 Camurus Ab Liquid depot formulations
WO2006085979A2 (en) 2004-07-09 2006-08-17 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of hendra and nipah virus g glycoprotein
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
NZ552480A (en) 2004-07-30 2010-01-29 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods of using same
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
ES2540853T3 (es) 2004-08-23 2015-07-14 Mannkind Corporation Sales de dicetopiperazina para la administración de fármacos
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
MX2007006120A (es) 2004-11-23 2007-12-07 Adamas Pharmaceuticals Inc Metodo y composicion para administrar a un sujeto un antagonista del receptor de nmda.
EP2623099A1 (en) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Composition and method for treating neurological disease
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
US8062644B2 (en) 2005-02-18 2011-11-22 Novartis Vaccines & Diagnostics Srl. Immunogens from uropathogenic Escherichia coli
MX2007012374A (es) 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
EP2062591A1 (en) 2005-04-07 2009-05-27 Novartis Vaccines and Diagnostics, Inc. CACNA1E in cancer diagnosis detection and treatment
EP2083088A3 (en) 2005-04-07 2009-10-14 Novartis Vaccines and Diagnostics, Inc. Cancer-related genes
RU2486204C2 (ru) 2005-07-22 2013-06-27 Уай'З Терапьютикс Ко., Лтд. Антитела против сd26 и способы их применения
US20070110674A1 (en) * 2005-07-29 2007-05-17 Yuhong Xu Sono-active liposomes and lipid particles and use thereof as contrast agents and active-agent delivery systems
DK1928423T3 (en) 2005-09-14 2016-02-29 Mannkind Corp A method for drug formulation based on increasing the affinity of the active substances to the crystalline microparticle surfaces
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007041481A1 (en) * 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
GEP20115333B (en) 2005-11-14 2011-11-25 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin generelated peptide and using same
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
CA2649109A1 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
SG172684A1 (en) 2006-06-07 2011-07-28 Bioalliance Cv Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
WO2009030978A2 (en) 2006-06-09 2009-03-12 Novartis Ag Conformers of bacterial adhesins
CA2659552A1 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
EP2134365B1 (en) 2007-03-21 2019-03-13 Effat Emamian Compositions and methods for inhibiting tumor cell growth
AP2009005028A0 (en) 2007-04-10 2009-12-31 Univ Tulane Soluble and membrane-anchored forms of lassa virussubunit proteins
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
EP3587450A1 (en) 2007-12-17 2020-01-01 Pfizer Limited Treatment of interstitial cystitis with ngf inhibitors
WO2009079649A1 (en) 2007-12-18 2009-06-25 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
EP2274437B1 (en) 2008-04-10 2015-12-23 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
CN102112110A (zh) * 2008-06-06 2011-06-29 米尔纳医疗股份有限公司 用于RNAi试剂体内递送的新型组合物
PL2293833T3 (pl) 2008-06-13 2016-08-31 Mannkind Corp Inhalator proszkowy i układ do dostarczania leku
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
US20110250266A1 (en) * 2008-10-07 2011-10-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Liposomal systems comprising sphingomyelin
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
AU2010220103A1 (en) 2009-03-06 2011-09-22 Novartis Ag Chlamydia antigens
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
ES2565377T3 (es) 2009-04-14 2016-04-04 Glaxosmithkline Biologicals Sa Composiciones para inmunización contra Staphylococcus aureus
WO2010138918A1 (en) * 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
MY157166A (en) 2009-06-12 2016-05-13 Mankind Corp Diketopiperazine microparticles with defined specific surface areas
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
AU2010272243A1 (en) 2009-07-16 2012-03-08 Novartis Ag Detoxified Escherichia coli immunogens
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
MX2012006320A (es) 2009-12-02 2013-01-18 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
SA114360064B1 (ar) 2010-02-24 2016-01-05 رينات نيوروساينس كوربوريشن طرق وأجسام مضادة معارضة ضد مستقبل il-7
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
CN105218674A (zh) 2010-03-11 2016-01-06 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
US9770414B2 (en) 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
MX359281B (es) 2010-06-21 2018-09-21 Mannkind Corp Sistema y metodos para suministrar un farmaco en polvo seco.
US8747844B2 (en) 2010-07-30 2014-06-10 Saint Louis University Methods of treating pain
WO2012058483A1 (en) * 2010-10-28 2012-05-03 Pacira Pharmaceuticals, Inc. A sustained release formulation of a non-steroidal anti-inflammatory drug
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
CN103153285B (zh) * 2010-12-27 2016-10-12 泰尔茂株式会社 脂质体组合物及其制造方法
KR101993431B1 (ko) 2011-01-06 2019-06-26 바이오노르 이뮤노 에이에스 단량체형 및 다량체형 면역원성 펩타이드
US10842849B2 (en) 2011-02-28 2020-11-24 The Schepens Eye Research Institute, Inc. Methods for promoting neuronal outgrowth by insulin-like growth factor binding protein-like 1 (IGFBPL-1) in glaucoma or leber's optic neuropathy
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (en) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions and methods for treating cancer
IN2014DN03093A (fi) 2011-10-24 2015-05-15 Mannkind Corp
RU2480479C1 (ru) * 2011-11-01 2013-04-27 Елена Викторовна Свирщевская Гетерологичный пептидный мини-антиген в составе полимерной частицы для создания противоаллергенной вакцины
CA2954166A1 (en) 2011-11-11 2013-05-16 Rinat Neuroscience Corp. Antibodies specific for trop-2 and their uses
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
RU2014123030A (ru) 2011-12-22 2016-02-20 Ринат Ньюросайенс Корп. Антагонистические антитела против человеческого рецептора гормона роста и способы их применения
IN2014MN02213A (fi) 2012-05-10 2015-07-10 Painreform Ltd
FR2991196B1 (fr) * 2012-05-29 2014-06-27 Capsum Nanoparticules ciblantes pour une application biologique
EP2864360B1 (en) 2012-06-25 2017-09-06 The Brigham and Women's Hospital, Inc. Targeted therapeutics
CA2877948C (en) 2012-07-02 2019-07-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Paramyxovirus and methods of use
CA2878457C (en) 2012-07-12 2021-01-19 Mannkind Corporation Dry powder drug delivery systems and methods
EP2877155B1 (en) 2012-07-26 2020-10-28 Camurus AB Opioid formulations
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
WO2014072876A1 (en) 2012-11-09 2014-05-15 Pfizer Inc. Platelet-derived growth factor b specific antibodies and compositions and uses thereof
WO2014083060A2 (en) 2012-11-30 2014-06-05 Novartis Ag Pseudomonas antigens and antigen combinations
CN105473154A (zh) 2013-03-12 2016-04-06 通用医疗公司 修饰的缪勒抑制物质(mis)蛋白及其用于疾病治疗的用途
SG10201708090TA (en) 2013-03-15 2017-11-29 Mannkind Corp Microcrystalline diketopiperazine compositions and methods
IL292121B2 (en) 2013-03-15 2024-02-01 Takeda Pharmaceuticals Co Anti-plasma kallikrein antibodies
EP3842443A1 (en) 2013-03-15 2021-06-30 Cerenis Therapeutics Holding SA Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
WO2014145042A1 (en) 2013-03-15 2014-09-18 Loma Linda University Treatment of autoimmune diseases
US9248189B2 (en) 2013-05-07 2016-02-02 Pfizer Inc. Anti-glucagon receptor antibodies and pharmaceutical compositions thereof
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
KR102321339B1 (ko) 2013-07-18 2021-11-02 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
FR3008900B1 (fr) * 2013-07-25 2018-03-30 Centre Nat Rech Scient Nanoparticules lipidiques multicompartimentees
MY190252A (en) 2013-08-02 2022-04-08 Pfizer Anti-cxcr4 antibodies and antibody-drug conjugates
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
SG11201602671WA (en) 2013-11-13 2016-05-30 Pfizer Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
CA2933335A1 (en) 2013-12-11 2015-06-18 The General Hospital Corporation Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
HRP20240159T1 (hr) 2014-03-21 2024-04-12 Teva Pharmaceuticals International Gmbh Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
WO2018048460A1 (en) 2014-04-21 2018-03-15 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
DK3134068T3 (da) 2014-04-21 2021-10-04 Heron Therapeutics Inc Langtidsvirkende polymerafgivelsessystemer
SI3134070T1 (sl) 2014-04-21 2021-03-31 Heron Therapeutics, Inc. Sestave poliortoestra in pomožne snovi iz organske kisline
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US20160206580A1 (en) * 2015-01-21 2016-07-21 Pacira Pharmaceuticals, Inc. Multivesicular liposome formulations of tranexamic acid
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
CN114773476A (zh) 2015-04-13 2022-07-22 辉瑞公司 治疗性抗体和它们的用途
US10877045B2 (en) 2015-07-21 2020-12-29 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
US10913802B2 (en) 2015-07-21 2021-02-09 Dyax Corp. Monoclonal antibody inhibitor of factor XIIA
WO2017015619A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
CN114163531A (zh) 2015-08-19 2022-03-11 辉瑞公司 组织因子途径抑制剂抗体及其用途
CA3036652A1 (en) 2015-09-15 2017-03-23 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
KR20180064541A (ko) 2015-10-23 2018-06-14 화이자 인코포레이티드 항-il-2 항체 및 조성물 및 이의 용도
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
SG11201805420SA (en) 2015-12-30 2018-07-30 Kodiak Sciences Inc Antibodies and conjugates thereof
WO2017117569A1 (en) 2015-12-30 2017-07-06 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
ES2904593T3 (es) 2016-01-21 2022-04-05 Pfizer Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos
CN109983013A (zh) 2016-11-18 2019-07-05 帕西拉制药有限公司 美洛昔康锌复合物微粒多囊脂质体制剂及其制备方法
KR102069670B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
JP2020510435A (ja) 2017-03-03 2020-04-09 ライナット ニューロサイエンス コーポレイション 抗ｇｉｔｒ抗体およびその使用方法
WO2018167621A1 (en) 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
EP3610010A4 (en) 2017-04-14 2021-02-24 Kodiak Sciences Inc. COMPLEMENT D-FACTOR ANTAGONIST ANTIBODIES AND THEIR CONJUGATES
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
CN111247167A (zh) 2017-06-02 2020-06-05 辉瑞公司 Flt3的特异性抗体及其用途
US20180358125A1 (en) 2017-06-13 2018-12-13 Alexander Bagaev Systems and methods for identifying cancer treatments from normalized biomarker scores
CA3069179A1 (en) 2017-07-13 2019-01-17 Massachusetts Institute Of Technology Targeting the hdac2-sp3 complex to enhance synaptic function
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
KR20210027230A (ko) 2017-10-04 2021-03-10 옵코 파마슈티칼스, 엘엘씨 암의 개인 맞춤형 치료에 관한 물품 및 방법
AU2019216420A1 (en) 2018-02-01 2020-08-20 Pfizer Inc. Chimeric antigen receptors targeting CD70
WO2019152705A1 (en) 2018-02-01 2019-08-08 Pfizer Inc. Antibodies specific for cd70 and their uses
PE20201342A1 (es) 2018-02-28 2020-11-25 Pfizer Variantes de il-15 y usos de las mismas
KR102602329B1 (ko) 2018-05-23 2023-11-16 화이자 인코포레이티드 Cd3에 특이적인 항체 및 이의 용도
TWI816396B (zh) 2018-05-23 2023-09-21 美商輝瑞大藥廠 特異性針對gucy2c之抗體及其用途
EP3994696A2 (en) 2019-07-03 2022-05-11 BostonGene Corporation Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control
US20220273568A1 (en) * 2019-07-12 2022-09-01 Pacira Pharmaceuticals, Inc. Multivesicular liposome formulations of dexmedetomidine
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
SG11202113226QA (en) * 2019-08-01 2021-12-30 Incarda Therapeutics Inc Antiarrhythmic formulation
US11788091B2 (en) 2019-08-21 2023-10-17 University Of Virginia Patent Foundation Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth
AU2020363372A1 (en) 2019-10-07 2022-05-19 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
US20240092935A1 (en) 2019-10-11 2024-03-21 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
JP2023515918A (ja) 2020-01-13 2023-04-17 デュレクト コーポレーション 不純物が低減された徐放性薬物送達システム及び関連の方法
EP4093426A1 (en) 2020-01-24 2022-11-30 University of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
EP4146688A1 (en) 2020-05-06 2023-03-15 CRISPR Therapeutics AG Mask peptides and masked anti-ptk7 antibodies comprising such
MX2023000662A (es) 2020-07-17 2023-02-27 Pfizer Anticuerpos terapeuticos y sus usos.
EP4189093A1 (en) 2020-07-30 2023-06-07 Pfizer Inc. Cells having gene duplications and uses thereof
AU2021338361A1 (en) 2020-09-03 2023-04-06 Chen, Irvin S.Y Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
WO2022120256A2 (en) 2020-12-04 2022-06-09 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
EP4330969A1 (en) 2021-04-29 2024-03-06 BostonGene Corporation Machine learning techniques for estimating tumor cell expression in complex tumor tissue
CA3227875A1 (en) 2021-08-02 2023-02-09 Pfizer Inc. Improved expression vectors and uses thereof
WO2023147177A1 (en) 2022-01-31 2023-08-03 Bostongene Corporation Machine learning techniques for cytometry
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
US20240029884A1 (en) 2022-07-15 2024-01-25 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)
CN115486539A (zh) * 2022-09-14 2022-12-20 厦门遇见今生生物科技有限公司 具有抗衰老及端粒延长的草药提取物仿生膜及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH588887A5 (fi) * 1974-07-19 1977-06-15 Battelle Memorial Institute
US4897308A (en) * 1975-06-30 1990-01-30 L'oreal Compositions comprising aqueous dispersions of lipid spheres
US4078052A (en) * 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
US4086257A (en) * 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (fi) * 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4310506A (en) * 1979-02-22 1982-01-12 California Institute Of Technology Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
JPS55153713A (en) * 1979-05-02 1980-11-29 Kureha Chem Ind Co Ltd Pharmaceutical preparation of ribosome containing active substance
US4394372A (en) * 1980-12-22 1983-07-19 The Procter & Gamble Company Process for making lipid membrane structures
US4522803A (en) * 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) * 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4599227A (en) * 1983-11-07 1986-07-08 Wisconsin Alumni Research Foundation Injectable pharmaceutical preparation for the induction of multiple follicular growth
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4975282A (en) * 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
IE58981B1 (en) * 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
FI860430A0 (fi) * 1986-01-29 1986-01-29 Imatran Voima Oy Foerfarande och anordning foer utnyttjande av vaermeenergi som frigoers i kylprocess.
US5204112A (en) * 1986-06-16 1993-04-20 The Liposome Company, Inc. Induction of asymmetry in vesicles
US4752425A (en) * 1986-09-18 1988-06-21 Liposome Technology, Inc. High-encapsulation liposome processing method
US4781871A (en) * 1986-09-18 1988-11-01 Liposome Technology, Inc. High-concentration liposome processing method
ATE87503T1 (de) * 1986-12-23 1993-04-15 Liposome Co Inc Liposomes praeparat und antibiotikum.
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
GB8704171D0 (en) * 1987-02-23 1987-04-01 Clayton Found Res Multivesicular liposomes
JP2666345B2 (ja) * 1987-04-16 1997-10-22 武田薬品工業株式会社 リポソーム製剤およびその製造法
IN168530B (fi) * 1987-11-06 1991-04-20 Lyphomed Inc
BE1001869A3 (fr) * 1988-10-12 1990-04-03 Franz Legros Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine.
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds

Also Published As

Publication number Publication date
JPH09505301A (ja) 1997-05-27
PT729351E (pt) 2000-12-29
PL314485A1 (en) 1996-09-16
CA2176712C (en) 2000-05-23
EP0729351A4 (en) 1998-02-04
US6132766A (en) 2000-10-17
RU2160093C2 (ru) 2000-12-10
WO1995013796A1 (en) 1995-05-26
CN1140989A (zh) 1997-01-22
ATE196248T1 (de) 2000-09-15
HUT75162A (en) 1997-04-28
EP0729351B1 (en) 2000-09-13
IL111628A0 (en) 1995-01-24
DK0729351T3 (da) 2000-10-16
IL111628A (en) 2002-08-14
AU1053595A (en) 1995-06-06
HU9601316D0 (en) 1996-07-29
DE69425901D1 (de) 2000-10-19
AU686277B2 (en) 1998-02-05
NO304577B1 (no) 1999-01-18
NZ276305A (en) 1997-10-24
ZA949063B (en) 1995-09-13
ES2149955T3 (es) 2000-11-16
DE69425901T2 (de) 2001-04-26
RO116341B1 (ro) 2001-01-30
FI962048A0 (fi) 1996-05-14
NO962024L (no) 1996-07-09
FI115823B (fi) 2005-07-29
EP0729351A1 (en) 1996-09-04
BG63146B1 (bg) 2001-05-31
KR100241300B1 (ko) 2000-03-02
JP3002702B2 (ja) 2000-01-24
CN1099868C (zh) 2003-01-29
BG100596A (bg) 1996-12-31
GR3034954T3 (en) 2001-02-28
BR9408072A (pt) 1997-08-12
CA2176712A1 (en) 1995-05-26
NO962024D0 (no) 1996-05-15

Similar Documents

Publication Publication Date Title
FI962048A (fi) Säädellysti vaikuttavia aineita vapauttavia rakkuloita
MX9701856A (es) Preparacion de liposomas multi-vesiculares para la liberacion controlada de agentes activos.
IL111734A0 (en) Compositions for the preparation of in vivo therapeutic products
PL323152A1 (en) Derivatives of 1,3-propanodiole as biologically active compounds
BR8801242A (pt) Processo de preparar uma composicao para fornecer uma quantidade efetiva de uma dose constante de um ingrediente ativo a um animal e a respectiva composicao
EP0973507A4 (en) PHARMACEUTICAL FORM WHICH DELETES RAPID DISPERSION PROPERTIES, METHOD OF USE, AND METHOD FOR THE PRODUCTION THEREOF
HK1031197A1 (en) Osmotic dosage form comprising first and second coats
EP0830369A4 (en) NOR-PREGNANE FOR INDUCING HYPOTHALAMIC EFFECTS
HUP9600116A3 (en) Fungicidal composition containing benzophenone, process for preparation of the active ingredients and method for the control of fungi.
IL117943A (en) Dihalopropene compounds and insecticides containing them as active ingredients
AU7092196A (en) Administration of biologically active material
ATE212550T1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
MX9703839A (es) Soluciones intravenosas de lubeluzol.
PL332035A1 (en) Transdermal therapeutic system including an estriol-containing composition of active substances
CS420088A1 (en) 1-/4-/3-alkoxy-3-alkyl-2-halogenbutoxy/phenyl/alkylester-3/2,2-di halogenethenyl/-2,2-dimethylcyclopropancarboxyl acids as biologically active substance and method of its preparation
HU902110D0 (en) Process for producing 1-phenyl-n-2-chlor-ethyl-carbamoil-7,8-dimethoxy-2,3,4,5-tetrahydro-1h-benzazepine and pharmaceutical preparatives containing these compounds as active agent
HUT55007A (en) Fungicidal and growth regulating compositions comprising vinylazole compounds and process for producing the active ingredients
MX9605633A (es) Composicion farmaceutica, metodo y dispositivo para prevenir o tratar resequedad de los ojos o enfermedad ocasionada por la misma.
AU2799995A (en) Sex reversion by altering biologically active amount of acat
MX9705592A (es) Composiciones farmaceuticas que contienen corticosteroides y preparacion de las mismas.

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 115823

Country of ref document: FI

MM Patent lapsed